Status:
UNKNOWN
Molecular Signatures of Cutaneous Squamous Cell Carcinoma During Recessive Dystrophic Epidermolysis Bullosa
Lead Sponsor:
Assistance Publique - Hôpitaux de Paris
Conditions:
Recessive Dystrophic Epidermolysis Bullosa
Eligibility:
All Genders
18+ years
Brief Summary
Recessive dystrophic epidermolysis bullosa (RDEB) is a hereditary skin disease characterized by cutaneous and mucosa fragility. Blister formations and erosions, resulting in chronic wounds and dystrop...
Eligibility Criteria
Inclusion
- for RDEB patients with a SCC :
- aged older than 18 years old
- one or more SCC surgically treated
- signed genetic consent form
- for non-RDEB patients with a SCC induced by ultraviolet radiation :
- aged older than 18 years old
- one or more SCC induced by ultraviolet radiation
- signed genetic consent form
Exclusion
- under protection by law (tutorship or curatorship)
- without health insurance coverage
Key Trial Info
Start Date :
March 1 2020
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 1 2023
Estimated Enrollment :
66 Patients enrolled
Trial Details
Trial ID
NCT04285294
Start Date
March 1 2020
End Date
December 1 2023
Last Update
February 26 2020
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.